Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus

Nina J Karlin; Aaron R Mangold; Shailja B Amin; Heidi E Kosiorek; Matthew R Buras; Patricia M Verona; Curtiss B Cook

doi:10.4155/fsoa-2018-0084

Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus

Future Sci OA. 2019 Mar 7;5(3):FSO368. doi: 10.4155/fsoa-2018-0084. eCollection 2019 Mar.

Authors

Nina J Karlin^{1

1}, Aaron R Mangold^{2

2}, Shailja B Amin^{1

1}, Heidi E Kosiorek^{3

3}, Matthew R Buras^{3

3}, Patricia M Verona^{4

4}, Curtiss B Cook^{5

5}

Affiliations

¹ Division of Hematology & Medical Oncology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, 85259, AZ, USA.
² Department of Dermatology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, 85259, AZ, USA.
³ Biostatistics, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, 85259, AZ, USA.
⁴ Department of Information Technology, Mayo Clinic Hospital, 577 E May Blvd, Phoenix, AZ, 85054, USA.
⁵ Division of Endocrinology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, 85259, AZ, USA.

Abstract

Aim: Given the lack of data in the literature, we examined the impact of diabetes mellitus (DM) on melanoma survival and the impact of melanoma on glycemic control.

Materials & methods: Patients with melanoma with and without DM were matched 1:1 (2005-2016). Kaplan-Meier analysis was used to estimate overall survival and progression-free survival (PFS). Mixed models compared hemoglobin A_1c (HbA_1c) and glucose measures over time.

Results: Mean HbA_1c during the year after cancer diagnosis was 6.7%. The 5-year PFS rate was 89% (95% CI: 81-99%) for patients with DM and 63% (95% CI: 51-79%) for patients without DM (p = 0.02).

Conclusion: Melanoma did not adversely impact glycemic control. The DM did not adversely impact survival of patients with melanoma, although increased PFS for melanoma was seen in individuals with DM.

Keywords: cancer; diabetes mellitus; endocrinology; glucose; malignancy; mortality; outcomes research.